Lexicon Pharmaceuticals, Inc.LXRXNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +980.25% | +3682.62% | +11.68% | +1652.64% | +710.40% |
| Gross Profit Growth | +983.23% | +0.00% | +29.01% | +1834.98% | +744.07% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +47.59% | +47.59% | +47.55% | +16.88% | +0.53% |
| Weighted Average Shares Diluted Growth | +47.59% | +47.59% | +47.55% | +16.97% | +0.53% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +810.38% | +243.86% | +3009.24% | -16.68% | -19.38% |
| Inventory Growth | +89.29% | -39.37% | -60.89% | -71.28% | -75.16% |
| Asset Growth | +16.15% | +30.07% | -28.65% | -39.58% | -35.87% |
| Book Value per Share Growth | -13.30% | +6.20% | -71.13% | -53.85% | -33.04% |
| Debt Growth | -4.53% | +2.20% | -4.24% | -46.05% | -42.54% |
| R&D Expense Growth | +46.83% | +80.77% | +7.56% | -11.74% | -27.24% |
| SG&A Expenses Growth | +22.85% | +0.00% | -63.79% | -76.14% | -80.80% |